Screener
Altimmune ALT Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Altimmune in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Altimmune’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326190-26-000040
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Research and development | 16,192 | 15,827 |
| General and administrative | 8,052 | 5,993 |
| Total operating expenses | 24,244 | 21,820 |
| Loss from operations | (24,244) | (21,815) |
| Other income (expense): | ||
| Interest expense | (1,068) | (1) |
| Interest income | 2,901 | 1,545 |
| Other income (expense), net | (152) | 15 |
Item 1. Financial Statements
FAQ
- What is Altimmune's operating income?
- Altimmune (ALT) reported operating income of -$24.24M in Q1 2026.
- How has Altimmune's operating income changed year-over-year?
- Altimmune's operating income decreased by 11.1% year-over-year, from -$21.82M to -$24.24M.
- What is the long-term trend for Altimmune's operating income?
- Over 4 years (2021 to 2025), Altimmune's operating income has grown at a -0.6% compound annual growth rate (CAGR), from -$96.91M to -$94.49M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Altimmune's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude